El 20 de julio de 2026, Jiangsu Hengrui Pharmaceuticals anunci que Ribupatide (HRS9531, conocido como KAI-9531 fuera de la Gran China), un agonista dual de los receptores GLP-1/GIP desarrollado de forma independiente por la compaa, obtuvo resultados positivos de primera lnea en un ensayo clnico de fase III realizado en pacientes chinos con diabetes tipo 2 sin tratamiento farmacolgico previo
Deletion of SLC25A39 was embryonically lethal at day E13.5 and embryos appeared pale, suggesting a severely anemic phenotype (Extended Data Fig
But depending on the individual, the most powerful reason might be cosmetic. There are different reasons why people want to lose weight
Kalil, Pablo Cirino, Carlos G
Generally, a higher concentration means a more potent product, but starting with a lower concentration is crucial to gauge your skin's tolerance